Revolution Medicines closed at $199.70 on Nov 4, up 2.82%, 9.7% below its 52-week closing high. Volume of 2.5M shares was 1.32× its 20-day average (above normal).
Split-adjusted performance: -0.1% over one month, +32.2% over six months, +236.6% over one year.
Short interest was 12.9M shares at the Oct 15 settlement, up 8.5% from the prior report (6.4% of float, 6.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RVMDRevolution Medicines | $199.70 | +2.82% | +32.2% | — | — | — | $42.80B | |
| BIIBBiogen | $254.46 | +2.22% | +33.4% | +10.6% | −0.7% | 108.2 | $37.61B | Compare |
| MRNAModerna | $258.38 | +13.11% | +429.6% | +2.1% | −539.3% | — | $103.15B | Compare |
| EXELExelixis | $72.75 | +0.61% | +49.4% | +10.2% | 33.1% | 20.1 | $17.75B | Compare |
| NBIXNeurocrine Biosciences | $166.05 | +0.73% | +12.9% | +41.2% | 18.4% | 24.0 | $16.88B | Compare |
| HALOHalozyme Therapeutics | $130.34 | +1.34% | +96.4% | +47.7% | 47.8% | 35.8 | $14.79B | Compare |
| KYMRKymera Therapeutics | $136.25 | +7.21% | +58.0% | −100.0% | — | — | $11.63B | Compare |
| TECHBio-Techne | $72.73 | +0.10% | +53.4% | +1.3% | 17.0% | 62.8 | $11.42B | Compare |
| RGENRepligen | $178.20 | −0.04% | +41.7% | +10.9% | −18.4% | — | $11.31B | Compare |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
